Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $20

Benzinga · 1d ago
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $22 to $20.